Synergistic anticancer effect of rAd/P53 combined with 5-fluorouracil or iodized oil in the early therapeutic response of human colon cancer in vivo

Gene

Volumn 499, Issue 2, 2012, Pages 303-308

  Xie, Qi ^a   Liang, Bi Ling ^b   Wu, Yan Heng ^c   Zhang, Jing ^a   Chen, Ming Wang ^a   Liu, Hong Yan ^a   Gu, Xiong Fei ^d   Xu, Jin ^a  

^a GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c JINAN UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

5 FU; Human colon cancer; Iodized oil; RAd p53; Xenograft model

Indexed keywords

FLUOROURACIL; GENDICINE; IODINATED POPPYSEED OIL; KI 67 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EFFECTIVENESS; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR NECROSIS; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; COLONIC NEOPLASMS; FLUOROURACIL; GENE THERAPY; HUMANS; IODIZED OIL; MICE; MICE, NUDE; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53;

MUS MUSCULUS;

EID: 84860250192     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.02.007     Document Type: Article

References (37)

1. Asmis T.R., Saltz L. Systemic therapy for colon cancer. Gastroenterol. Clin. North Am. 2008, 37:287-295.
2. Baek J.H., et al. In vivo recombinant adenovirus-mediated P53 gene therapy in a syngeneic rat model for colorectal cancer. J. Korean Med. Sci. 2004, 19:831-841.
3. Baker S.J., et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989, 244:217-221.
4. Bedi A., et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res. 1995, 55:1811-1816.
5. Bookstein R., Demers W., Gregory R., Maneval D., Park J., Wills K. p53 gene therapy in vivo of hepatocellular and liver metastatic colorectal cancer. Semin. Oncol. 1996, 23:66-77.
6. Bozzetti F., et al. Comparing surgical resection of limited hepatic metastases from colorectal cancer to non-operative treatment. Eur. J. Surg. Oncol. 1993, 19:162-167.
7. Fujiwara T., Grimm E.A., Mukhopadhyay T., Zhang W.W., Owen-Schaub L.B., Roth J.A. Induction of chemosensitivity in human lung cancer cells in vivo by adenoviral-mediated transfer of the wild-type p53 gene. Cancer Res. 1994, 54:2287-2291.
8. Guan Y.S., Liu Y., Sun L., Li X., He Q. Successful management of postoperative recurrence of hepatocellular carcinoma with p53 gene therapy combining transcatheter arterial chemoembolization. World J. Gastroentrol. 2005, 11:3803-3805.
9. Guan Y.S., La Z., Yang L., He Q., Li P. p53 gene in treatment of hepatic carcinoma: status quo. World J. Gastroenterol. 2007, 13:985-992.
10. Hollstein M., Sidransky D., Vogelstein B. p53 mutations in human cancers. Science 1991, 253:49-53.
11. Hughes K.S., et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of long-term survivors. Dis. Colon Rectum 1988, 31:1-4.
12. Inoue H., et al. Adenoviral-mediated transfer of p53 gene enhances TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Int. J. Mol. Med. 2004, 14:271-275.
13. Jemal A., et al. American Cancer Society. Cancer statistics. CA Cancer J. Clin. 2004, 54:8-29.
14. Jo H.J., Song J.D., Kim K.M., Cho Y.H., Kim K.H., Park Y.C. Diallyl disulfide induces reversible G2/M phase arrest on a p53-independent mechanism in human colon cancer HCT-116 cells. Oncol. Rep. 2008, 19:275-280.
15. Kaufmann S.H., Vaux D.L. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003, 22:7414-7430.
16. Kim Y.I., Chung J.W., Park J.H., Han J.K., Hong J.W., Chung H. Intraarterial gene delivery in rabbit hepatic tumors: transfection with nonviral vector by using iodized oil emulsion. Radiology 2006, 240:771-777.
17. Levine A.J., Momand J., Finlay C.A. The p53 tumor suppressor gene. Nature 1991, 351:453-456.
18. Li Y.X., Lin Z.B., Tan H.R. Wild type p53 increased chemosensitivity of drug resistant human hepatocellular carcinoma Bel7402/5-FU cells. Acta Pharmacol. Sin. 2004, 25:76-82.
19. Lim D.S., et al. Adenovirus-mediated p53 treatment enhances photodynamic antitumor response. Hum. Gene Ther. 2006, 17:347-352.
20. Liu B., et al. Adenovirus-mediated p53 gene transfer sensitizes hepatocellular carcinoma cells to heavy-ion radiation. J. Gastroenterol. 2007, 42:140-145.
21. Lowe S.W., et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994, 266:807-810.
22. Menon A.G., et al. Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients. Cancer Gene Ther. 2003, 10:509-517.
23. Mow B.M., Blajeski A.L., Chandra J., Kaufmann S.H. Apoptosis and the response to anticancer therapy. Curr. Opin. Oncol. 2001, 13:453-462.
24. Nguyen D.M., et al. Delivery if the p53 tumor suppressor gene into lung cancer cells by an adenovirus/DNA complex. Cancer Gene Ther. 1997, 4:191-198.
25. Norris J.S., et al. The present and future for gene and viral therapy of directly accessible prostate and squamous cell cancers of the head and neck. Future Oncol. 2005, 1:115-123.
26. Parker S.L., Tong T., Bolden S., Wingo P.A. Cancer statistics. CA Cancer J. Clin. 1997, 47:5-27.
27. Petak I., Tillman D.M., Houghton J.A. p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines. Clin. Cancer Res. 2000, 6:4432-4441.
28. Pozzo C., Barone C., Kemeny N.E. Advances in neoadjuvant therapy for colorectal cancer with liver metastases. Cancer Treat. Rev. 2008, 34:293-301.
29. Roth J.A. Adenovirus p53 gene therapy. Expert Opin. Biol. Ther. 2006, 6:55-61.
30. Ruifa H., Liwei L., Binxin L., Ximing L. Additional gene therapy with rAAV-wt-p53 enhanced the efficacy of cisplatin in human bladder cancer cells. Urol. Int. 2006, 77:355-361.
31. Shiba H., Okamoto T., Futagawa Y., Ohashi T., Eto Y. Efficient and cancer-selective gene transfer to hepatocellular carcinoma in a rat using adenovirus vector with iodized oil esters. Cancer Gene Ther. 2001, 8:713-718.
32. Shimada H., et al. Preclinical study of adenoviral p53 gene therapy for esophageal cancer. Surg. Today 2001, 31:597-604.
33. Shimada H., et al. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci. 2006, 97:554-561.
34. Spitz F.R., Nguyen D., Skibber J.M., Cusack J., Roth J.A., Cristiano R.J. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res. 1996, 16:3415-3422.
35. Spitz F.R., Nguyen D., Skibber J.M., Meyn R.E., Cristiano R.J., Roth J.A. Adeniviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin. Cancer Res. 1996, 2:1665-1671.
36. Xie Q., et al. In vivo comparison of transduction efficiency with recombinant adenovirus-mediated p53 in a human colon cancer mouse model by different delivery routes. Chin. Ger. J. Clin. Oncol. 2008, 7:704-708.
37. Yu Z.W., et al. Reversal of 5-flouroucial resistance by adenovirus-mediated transfer of wild-type p53 gene in multidrug-resistant human colon carcinoma LoVo/5-FU cells. World J. Gastroenterol. 2004, 10:1979-1983.